Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year 2017 Results; Teleconference and Webcast to be held on September 25, 2017
CRANBURY, N.J., Sept. 25, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its fourth quarter and fiscal year ended June 30, 2017. Recent and Fiscal Year Significant Highlights Bremelanotide …